Peripheral and intestinal CD4+ T cells with a regulatory phenotype in pediatric patients with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 5, 2010, Pages 563-572

  La Scaleia, Raffaella ^a   Morrone, Stefania ^a   Stoppacciaro, Antonella ^b   Scarpino, Stefania ^b   Antonelli, Manila ^a   Bianchi, Elettra ^a   Di Nardo, Giovanni ^b   Oliva, Salvatore ^b   Viola, Franca ^b   Cucchiara, Salvatore ^b   Santoni, Angela ^a   Palmieri, Gabriella ^a   Uccini, Stefania ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Crohn disease; inflammatory bowel disease; natural killer; regulatory T cells; ulcerative colitis

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL POPULATION; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENTERITIS; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INTESTINE INJURY; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SCHOOL CHILD; T LYMPHOCYTE SUBPOPULATION;

CASE-CONTROL STUDIES; CHILD; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY;

EID: 78149285496     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181e4d323     Document Type: Article

References (50)

1. Calkins BM, Mendeloff AI. The epidemiology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter RG, eds. Inflammatory Bowel Disease. Philadelphia: Williams & Wilkins; 1995:31-68.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
3. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
5. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;307:1920-5.
6. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8:458-66.
7. Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet 2008;9:9-14.
8. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
9. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007;102:2058-69.
10. Elson CO, Cong Y, McCracken VJ, et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005;206:260-76.
11. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005;206:296-305.
12. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 2005;206:277-95.
13. Coombes JL, Robinson NJ, Maloy KJ, et al. Regulatory T cells and intestinal homeostasis. Immunol Rev 2005;204:184-94.
14. Tang Q, Bluestone JA. The Foxp3\+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008;9:239-44.
15. Huibregtse IL, van Lent AU, van Deventer SJ. Immunopathogenesis of IBD: insufficient suppressor function in the gut? Gut 2007;56:584-92.
16. Baecher-Allan C, Wolf E, Hafler DA. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4\+ CD25\+ T cells. Clin Immunol 2005;115:10-8.
17. Makita S, Kanai T, Oshima S, et al. CD4\+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004;173:3119-30.
18. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4\+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868-78.
19. Holmén N, Lundgren A, Lundin S, et al. Functional CD4\+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 2006;12:447-56.
20. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007;120:744-50.
21. Shevach EM, DiPaolo RA, Andersson J, et al. The lifestyle of naturally occurring CD4\+ CD25\+ Foxp3\+ regulatory T cells. Immunol Rev 2006;212:60-73.
22. Seddiki N, Santner-Nanan B, Martinson J, et al. Zaunders J, Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203: 1693-700.
23. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4\+ T reg cells. J Exp Med 2006;203:1701-11.
24. Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4\+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007;319:41-52.
25. Yu QT, Saruta M, Avanesyan A, et al. Expression and functional characterization of FOXP3\+CD4\+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2007;13:191-9.
26. Saruta M, Yu QT, Fleshner PR, et al. Characterization of FOXP3\+ CD4\+ regulatory T cells in Crohn's disease. Clin Immunol 2007; 125:281-90.
27. Kelsen J, Agnholt J, Hoffmann HJ, et al. FoxP3(\+)CD4(\+)CD25(\+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol 2005; 141:549-57.
28. Yokoyama Y, Fukunaga K, Fukuda Y, et al. Demonstration of low-regulatory CD25high\+CD4\+ and high-pro-inflammatory CD28-CD4\+ T-cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007; 52:2725-31.
29. Takahashi M, Nakamura K, Honda K, et al. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci 2006;51:677-86.
30. Bousvaros A, Morley-Fletcher A, Pensabene L, et al. Research and clinical challenges in paediatric inflammatory bowel disease. Dig Liver Dis 2008;40:32-8.
31. Nieuwenhuis EE, Escher JC. Early onset IBD: what's the difference? Dig Liver Dis 2008;40:12-5.
32. Bausvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: reports of a Working Group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007;44:653-74.
33. Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997;113:118-26.
34. Arseneau KO, Tamagawa H, Pizarro TT, et al. Innate and adaptive immune responses related to IBD pathogenesis. Curr Gastroenterol Rep 2007;9:508-12.
35. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immu-noregulation varies in early and late inflammatory bowel disease. Gut 2007;56:1696-705.
36. Pappa HM, Semrin G, Walker TR, et al. Pediatric inflammatory bowel disease. Curr Opin Gastroenterol 2004;20:333-40.
37. Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007;16:164-71.
38. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
39. Loonen HJ, Griffiths AM, Merkus MP, et al. A critical assessment of items on the pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterl Nutr 2003;36:90-5.
40. Perminow G, Reikvam DH, Lyckander LG, et al. Increased number and activation of colonic macrophages in pediatric patients with untreated Crohn's disease. Inflamm Bowel Dis 2009;15:1368-78.
41. Selby WS, Janossy G, Bofill M, et al. Intestinal lymphocyte subpopula-tions in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut 1984;25:32-40.
42. Van Tol EA, Verspaget HW, Peña AS, et al. Normal inflammatory bowel disease mucosa conceals alterations in natural killer cell activity. Scand J Gastroenterol 1992;27:999-1005.
43. Van Tol EA, Verspaget HW, Peña AS, et al. The CD56 adhesion molecule is the major determinant for detecting non-major histocom-patibility complex-restricted cytotoxic mononuclear cells from the intestinal lamina propria. Eur J Immunol 1992;22:23-9.
44. Lanier LL, Chang C, Azuma M, et al. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol 1991;146:4421-6.
45. Andoniou CE, Coudert JD, Degli-Esposti MA. Killers and beyond: NK-cell-mediated control of immune responses. Eur J Immunol 2008; 38:2938-42.
46. Münz C. Non-cytotoxic protection by human NK cells in mucosal secondary lymphoid tissues. Eur J Immunol 2008;38:2946-8.
47. Pittet MJ, Speiser DE, Valmori D, et al. Cutting edge: cytolytic effector function in human circulating CD8\+ T cells closely correlates with CD56 surface expression. J Immunol 2000;164:1148-52.
48. Hogan PG, Gibson PR, Hapel AJ, et al. Intestinal lymphokine-activated killer cells in inflammatory bowel disease. J Gastroenterol Hepatol 1991;6:455-60.
49. Yuan Q,Bromley SK, Means TK,etal. CCR4-dependentregulatoryTcell function in inflammatory bowel disease. J Exp Med 2007;204:1327-34.
50. Denning TL, Kim G, Kronenberg M. Cutting edge: CD4\+CD25\+ regulatory T cells impaired for intestinal homing can prevent colitis. J Immunol 2005;174:7487-91.